Phathom Pharmaceuticals
PHAT
79 hedge funds and large institutions have $843M invested in Phathom Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 14 reducing their positions, and 17 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 14
1.14% more ownership
Funds ownership: 78.4% → 79.54% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less funds holding
Funds holding: 84 → 79 (-5)
8% less capital invested
Capital invested by funds: $919M → $843M (-$75.8M)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.3M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$6.14M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.41M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.13M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.74M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$7.92M |
| 3 |
JP Morgan Chase
New York
|
-$6.52M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.01M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.56M |
PHAT Hedge Fund Activity: Q2 2021 in Review
79 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2021, worth a combined $843M — down 8.2% from $919M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PHAT and 12 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 34 added.
The largest buyer was BlackRock, adding an estimated $12.3M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $9.74M.
- 79 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2021, down from 84 in Q1 2021.
- Funds reported $843M of Phathom Pharmaceuticals stock for Q2 2021, down 8.2% quarter-over-quarter.
- 12 funds opened new Phathom Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of -5 holders.
- The largest Phathom Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $12.3M added.
- The largest Phathom Pharmaceuticals seller in Q2 2021 was Gilder Gagnon Howe & Co, an estimated $9.74M sold.
Based on aggregated 13F filings for Q2 2021.